Cellulitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]

Cellulitis Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Cellulitis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cellulitis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cellulitis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cellulitis medical therapy
CDC on Cellulitis medical therapy
Cellulitis medical therapy in the news
Blogs on Cellulitis medical therapy
Directions to Hospitals Treating Cellulitis
Risk calculators and risk factors for Cellulitis medical therapy

Overview

Beta-lactam antibiotics against Streptococcus and penicillinase-producing Staphylococcus aureus are the usual drugs of choice. Ancillary measures include elevation of the affected area to reduce fluid accumulation and cool sterile saline dressings to remove purulent debris from open wounds.

Medical Therapy

• Mostly the causative agent is streptococci (often group A, but also from other groups, such as B, C, or G) and rarely staphylococcus aureus that is associated with penetrating trauma, illicit drug use.
• Cultures of needle aspirations from inflammed skin, blood or punch biopsies are variable and not useful in the setting of mild infection and hence performed in patients with systemic toxicity, underlying comorbidities (immunodeficiency, diabetes etc) and special exposures (animal bites).
• The antibiotic selection for treatment of cellulitis depends on whether the clinical presentation is purulent or nonpurulent, as purulent cellulitis is potentially attributable to staphylococcus aureus, which should be empirically treated with Beta-lactam antibiotics. Latest reports suggest that this bacterium has acquired resistance (MRSA) and newer drugs are to be used to kill off the pathogen. Reports from the laboratory regarding the sensitivity of the pathogen is a key factor in deciding the therapy.
• Choice of the antibiotic therapy for cellulitis depends on the following factors:
  • Age of the individual: Early hospitalization and parenteral therapy are required for treatment of cellulitis in neonates, except for the mildest of cases.
  • Co-morbid conditions
  • Site of lesion
  • Severity of lesion
  • Pathogen involved (gram positive or negative and aerobic or anaerobic)
  • Strain and resistance of the pathogen
• Parenteral therapy is indicated for severely ill patients or for those unable to tolerate oral medications.
• The duration of antibiotic therapy in immunocompetent individuals is until 3 days after acute inflammation disappears.

Uncomplicated Cellulitis

• Simple infection without abscesses or drainage should be managed with empiric therapy for infection due to beta-hemolytic streptococci and methicillin sensitive staphylococcus aureus (MSSA).
• Patients allergic to penicillin drugs can be given macrolide antibiotics like azithromycin.

• According to the 2011 clinical practice guidelines, if both methicillin resistant staphylococcus aureus and Streptococcus pyogenes are possible causes, then "options include the following: clindamycin alone (A-II) or TMP-SMX or a tetracycline in combination with a β-lactam (eg, amoxicillin) (A-II) or linezolid alone (A-II)." MRSA is commonly the causative agent of cellulitis in cases presenting with abscesses. In mild cases, treatment will be TMP-SMX with doxycycline and in severe cases, the most cost effective therapy will be vancomycin.

• According to the 2005 clinical practice guidelines, which state that staphylococcus aureus is very uncommon: "Suitable agents include dicloxacillin, cephalexin, clindamycin, or erythromycin, unless streptococci or staphylococci resistant to these agents are common in the community." Another trial confirms that if purulence or diabetes are not present then coverage for staphylococcus aureus is not needed.

• A study of failed treatment concluded that failure is reduced if higher dose antibiotics are used:
  • Vancomycin at least 30 mg/kg/day
  • Clindamycin at least 10 mg/kg/day (450 mg every 8 hours)
  • TMP-SMX at least 5 mg/kg/day of trimethoprim (a single strength pill has 80 mg trimethoprim) (two double strength pills every 12 hours)
  • If levofloxacin is used for treatment, 5 days is as effective as 10 days. However, levofloxacin is ineffective against methicillin-resistant Staphylococcus aureus.

Severe Cellulitis

• In severe cases of the disease, parenteral therapy is advocated.
• Patients who do not respond to initial therapy, or with signs of systemic illness, or with recurrent infection in the setting of underlying predisposing conditions, or with risk factors for MRSA, or in communities where the prevalence of MRSA is greater, additional empiric coverage for MRSA is considered.
• Patients with a penicillin allergy can be given vancomycin and clindamycin.
• In diabetic individuals, broad coverage antibiotics are used. Carbapenams, beta-lactam antibiotics with Beta-lactamase inhibitors are given in a combined regimen for antibiotic coverage.
• The duration of therapy should be individualized depending on clinical response; 5 to 10 days is usually appropriate (7 to 10 days in neonates); longer duration of therapy may be warranted in patients with severe disease.

Empiric TherapyAdapted from Clinical Practice Guidelines CID 2011 and Guidelines for Skin and Soft-Tissue Infections CID 2005

▸ Click on the following categories to expand treatment regimens.

Cellulitis Non-Purulent Cellulitis   ▸  Adults   ▸  Children age >28 days Purulent Cellulitis   ▸  Adults   ▸  Children age >28 days Complicated Cellulitis†   ▸  Adults   ▸  Children age >28 days

Non-Purulent Cellulitis Preferred Regimen ▸ Cephalexin 500 mg PO q6h x5-10 days OR ▸ Dicloxacillin 500 mg PO q6h x5-10 days OR ▸Clindamycin 300-450 mg PO q8h OR ▸ Amoxicillin 500 mg PO q8h OR ▸ TMP-SMX 80-160 mg/400-800 mg PO q12h OR ▸Doxycycline 100 mg PO q12h OR ▸ Linezolid 600 mg PO q12h Non-Purulent Cellulitis Preferred Regimen ▸ Cephalexin 25 mg/kg/day PO divided q6h x 5-10 days OR ▸ Dicloxacillin 25 mg/kg/day PO divided q6h x 5-10 days OR ▸ Clindamycin 10-13 mg/kg IV q6-8h (max:40 mg/kg/day) OR ▸ TMP-SMX 4-6 mg/kg PO q12h (TMP component) OR ▸Doxycycline¶ 2 mg/kg PO q12h† OR ▸ Linezolid 10 mg/kg PO q8h (max: 600mg/dose) ¶ Not recommended for children < 8 years of age † For children ≤45 kg. Children >45 kg receive adult dosing. Purulent Cellulitis Preferred Regimen ▸ Linezolid 600 mg PO q12h OR ▸ Clindamycin 300 - 450 mg PO q8h OR ▸ Minocycline 200 mg PO 1 dose, then 100 mg PO q12h OR ▸ Doxycycline 100 mg PO q12h OR ▸ TMP-SMX 80-160 mg/400-800 mg PO q12h Purulent Cellulitis Preferred Regimen ▸ Linezolid 10 mg/kg PO q8h (max: 600mg/dose) OR ▸ Clindamycin 10-13 mg/kg IV q6-8h (max:40 mg/kg/day) OR ▸ Minocycline 4 mg/kg PO 1 dose, then2 mg/kg/dose PO q12h OR ▸ Doxycycline¶ 2 mg/kg PO q12h† OR ▸ TMP-SMX 4-6 mg/kg PO q12h (TMP component) ¶ Not recommended for children < 8 years of age † For children ≤45 kg. Children >45 kg receive adult dosing. Complicated Cellulitis Parental Regimen Preferred Regimen ▸ Vancomycin 15-20 mg/kg IV q8-12h OR ▸ Linezolid 600 mg IV q12h OR ▸ Daptomycin 4mg/kg IV q24h OR ▸ Telavancin 10mg/kg IV q24h Alternative Regimen ▸ Clindamycin 600 mg IV q8h Oral Regimen Preferred Regimen ▸ Linezolid 600 mg PO q12h Alternative Regimen ▸ Clindamycin 600 mg PO q8h † Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis Complicated Cellulitis Parental Regimen Preferred Regimen ▸ Vancomycin 15 mg/kg IV q6h OR ▸ Linezolid 10 mg/kg IV q8h (max: 600mg/dose) Alternative Regimen ▸ Clindamycin 10-13 mg/kg IV q6-8h (max:40 mg/kg/day) Oral Regimen Preferred Regimen ▸ Linezolid 10 mg/kg PO q8h (max: 600mg/dose) OR ▸ Clindamycin 10-13 mg/kg PO q6-8h (max:40 mg/kg/day) † Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis

Note:

• The treatment of cellulitis in neonates usually requires hospitalization and parenteral therapy. Oral therapy is given for completion of the treatment when the pathogen is unknown.
• Optimal dose should be based on determination of serum concentrations.
• The above antibiotic regimen is NOT for initial empirical treatment of infections involving the face.
• Patients with renal insufficiency may require dose adjustment in case of cephalosporins.
• Clindamycin is an alternate therapy for patients at risk of severe hypersensitivity reaction to penicillins and cephalosporins.
• Doxycycline is NOT recommended for children <8 years of age.
• Studies have shown an increase in treatment failure with TMP-SMX compared to other agents for cellulitis in children, reflecting TMP-SMX less action against Group A streptococcus.

Special Cases

Orbital Cellulitis

• Treatment regimens are usually empiric and designed to address the usual pathogens like Streptococcus pneumoniae, Hemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, anaerobes (when intracranial extension is suspected), group A streptococci, and sometimes gram negative bacilli because, in the absence of surgical intervention, reliable culture results are difficult to obtain.

▸ Click on the following categories to expand treatment regimens.

Orbital Cellulitis   ▸  Usual pathogens   ▸  MRSA

Usual pathogens Preferred Regimen ▸ Nafcillin 2 gm IV q4h PLUS ▸ Ceftriaxone 2 gm IV q24h PLUS ▸ Metronidazole 1 gm IV q12h Alternative Regimen ▸ Vancomycin 1 gm IV q12h PLUS ▸ Levofloxacin 750 mg IV once daily PLUS ▸ Metronidazole 1 gm IV q12h MRSA Preferred Regimen ▸ Vancomycin 1 gm IV q12h PLUS ▸ Ceftriaxone 2 gm IV q24h PLUS ▸ Metronidazole 1 gm IV q12h Alternative Regimen ▸ Daptomycin 6 mg/kg IV q24h PLUS ▸ Levofloxacin 750 mg IV once daily OR ▸ Ceftriaxone 2 gm IV q24h PLUS ▸ Metronidazole 1 gm IV q12h

• Bite Wounds (Mammalian).
  • Bite wounds suffered from a mammal often contain polymicrobial sources that are anaerobic in nature.
  • Mild cases can be treated with amoxicillin and clavulanate, and in cases of penicillin allergy cotrimoxazole along with metronidazole is used.
  • In severe cases, piperacillin and tazobactum are used.

• Acquatic punctures and lacerations.
  • This is seen mainly in professional swimmers and divers both in freshwater and in brackish water.
  • Failure to recognize these wounds and delay treatment may cause a larger morbidity.
  • Wounds in fresh water are treated with doxycycline and ceftazidime (or fluroquinolones).
  • Wounds in brackish water are treated with ceftazidime and levofloxacin.

Non-Antibiotic Therapy

• Elevation of the affected area facilitates gravity drainage of edema and inflammatory substances. Compressive stockings and diuretic therapy may help patients with edema.
• The skin should be sufficiently hydrated to avoid dryness and cracking without maceration.